Brooklyn ImmunoTherapeutics Inc News - BTX

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...

Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...

Notice of Effectiveness (effect)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:June 04,

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-256570 PROSPECTUS ...

Securities Registration: Employee Benefit Plan (s-8)

As filed with the Securities and Exchange Commission on June 3, 2021. Registration No. 333- UNITED STATES SECURITIES AND...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...

Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company’s Future During May 25, 2021 Shareholde...

Replay of Presentation is Now Available on the Company’s Website Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a...

Amended Statement of Ownership (sc 13g/a)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule...

Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing

Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company currently focused on exploring the role that...

Statement of Ownership (sc 13g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.

Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL...

Statement of Ownership (sc 13g)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule...

Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET

Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn" or the “Company”), a biopharmaceutical company currently focused on exploring...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Brooklyn ImmunoTherapeutics Inc (BTX)

Empower your portfolio: Real-time discussions and actionable trading ideas.

BTX News

Current Report Filing (8-k)

Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics

Current Report Filing (8-k)

Notice of Effectiveness (effect)

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

Securities Registration: Employee Benefit Plan (s-8)

Current Report Filing (8-k)

Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company’s Future During May 25, 2021 Shareholde...

Amended Statement of Ownership (sc 13g/a)

Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing

Statement of Ownership (sc 13g)

Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.

Initial Statement of Beneficial Ownership (3)

Statement of Ownership (sc 13g)

Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET

BTX Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Brooklyn ImmunoTherapeutics Inc (BTX) News

Brooklyn ImmunoTherapeutics Inc (BTX)

Empower your portfolio: Real-time discussions and actionable trading ideas.

BTX News

Current Report Filing (8-k)

Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics

Current Report Filing (8-k)

Notice of Effectiveness (effect)

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

Securities Registration: Employee Benefit Plan (s-8)

Current Report Filing (8-k)

Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company’s Future During May 25, 2021 Shareholde...

Amended Statement of Ownership (sc 13g/a)

Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing

Statement of Ownership (sc 13g)

Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.

Initial Statement of Beneficial Ownership (3)

Statement of Ownership (sc 13g)

Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET

BTX Discussion

Your Recent History